LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "new oral" as a keyword



Photo from wikipedia

Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.

Sign Up to like & get
recommendations! Published in 2021 at "JAMA internal medicine"

DOI: 10.1001/jamainternmed.2021.5983

Abstract: Importance Launch prices of new cancer drugs in the US have substantially increased in recent years despite growing concerns about the quantity and quality of evidence supporting their approval by the US Food and Drug… read more here.

Keywords: cancer drugs; 2011 2018; targeted cancer; cancer ... See more keywords

Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID‐19: Challenges in Pharmacoepidemiologic Research

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Clinical Pharmacology"

DOI: 10.1002/jcph.2195

Abstract: Since the beginning of the COVID-19 pandemic, efforts have been made to develop new therapies for COVID19.1,2 The drugs developed in the meantime focus on completing a COVID-19 response strategy to prevent serious illness, hospitalization,… read more here.

Keywords: evidence new; uncertainties evidence; embracing uncertainties; evidence ... See more keywords
Photo from archive.org

The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.

Sign Up to like & get
recommendations! Published in 2017 at "Advances in experimental medicine and biology"

DOI: 10.1007/5584_2016_112

Abstract: New oral anticoagulants (NOACs) are likely to have a major impact in the next few years, changing clinical practice of anticoagulation therapy. Evidence on its efficacy and superiority to vitamin K antagonists (VKAs) in treating… read more here.

Keywords: oral anticoagulants; anticoagulants noacs; role new; cancer ... See more keywords

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Thrombosis and Thrombolysis"

DOI: 10.1007/s11239-020-02319-w

Abstract: New oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with… read more here.

Keywords: thromboembolic events; risk; oral anticoagulants; major bleeding ... See more keywords

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey

Sign Up to like & get
recommendations! Published in 2024 at "Dermatology and Therapy"

DOI: 10.1007/s13555-023-01089-6

Abstract: While multiple treatments are available for moderate to severe psoriasis, patient preferences are rarely systematically studied. This study aims to identify factors associated with choice of a new once-daily oral psoriasis treatment, elicit patient views… read more here.

Keywords: moderate severe; treatment; new oral; psoriasis ... See more keywords
Photo from wikipedia

Tofacitinib: A New Oral Therapy for Psoriasis

Sign Up to like & get
recommendations! Published in 2017 at "Clinical Drug Investigation"

DOI: 10.1007/s40261-017-0596-y

Abstract: Psoriasis is a common, chronic, immune-mediated disease associated with several comorbidities. Biologic therapy revolutionized the treatment of moderate-to-severe psoriasis, improving physical and emotional burden of the disease. Still, there are unmet needs in the treatment… read more here.

Keywords: tofacitinib new; therapy; treatment; oral therapy ... See more keywords
Photo from wikipedia

New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting

Sign Up to like & get
recommendations! Published in 2020 at "Clinical Drug Investigation"

DOI: 10.1007/s40261-020-00926-2

Abstract: Background and Objective Recent trials showed that thromboprophylaxis with new oral anticoagulants (NOACs) is effective and safe in patients with cancer initiating chemotherapy. However, the cost effectiveness of NOACs is unknown. The objective of this… read more here.

Keywords: oral anticoagulants; patients cancer; new oral; cost ... See more keywords
Photo by nci from unsplash

TCT-808 Comparison between Clopidogrel and the New Oral P2Y12 Inhibitors in the Treatment of Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention

Sign Up to like & get
recommendations! Published in 2018 at "Journal of the American College of Cardiology"

DOI: 10.1016/j.jacc.2018.08.2043

Abstract: Dual antiplatelet therapy improves angiographic results of primary percutaneous coronary intervention (pPCI) in patients with STEMI. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor are the gold-standard drugs because of a faster and more… read more here.

Keywords: oral p2y12; primary percutaneous; percutaneous coronary; coronary intervention ... See more keywords

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Sign Up to like & get
recommendations! Published in 2022 at "Annals of Medicine"

DOI: 10.1080/07853890.2022.2034936

Abstract: Abstract Background The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have been made in COVID-19 research and many antiviral drugs have shown good therapeutic effects against COVID-19, a simple oral… read more here.

Keywords: oral antiviral; molnupiravir fluvoxamine; covid; covid patients ... See more keywords

PD26-05 EFFECTS OF A NEW ORAL TESTOSTERONE UNDECANOATE (TLANDO) THERAPY ON LIVER

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Urology"

DOI: 10.1097/ju.0000000000000883.05

Abstract: INTRODUCTION AND OBJECTIVE:Oral methyltestosterone (MT) was approved for a testosterone replacement therapy (TRT) in males with a deficiency of endogenous testosterone. Due to its liver toxicity, t... read more here.

Keywords: oral testosterone; effects new; testosterone; pd26 effects ... See more keywords

A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism

Sign Up to like & get
recommendations! Published in 2022 at "Andrology"

DOI: 10.1111/andr.13153

Abstract: Male hypogonadism (testosterone level < 300 ng/dl) is a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone. Most marketed testosterone replacement therapy products often require multiple dose adjustment… read more here.

Keywords: male hypogonadism; testosterone tlando; new oral; testosterone ... See more keywords